Risk of CFTR-related disorders and cystic fibrosis in an Italian cohort of CRMS/CFSPID subjects in preschool and school age.
CFTR-RD
Children
Cystic fibrosis inconclusive diagnosis
FEV1
LCI
Neonatal screening
Outcomes
Sweat test
Journal
European journal of pediatrics
ISSN: 1432-1076
Titre abrégé: Eur J Pediatr
Pays: Germany
ID NLM: 7603873
Informations de publication
Date de publication:
06 Dec 2023
06 Dec 2023
Historique:
received:
13
09
2023
accepted:
29
11
2023
revised:
27
11
2023
medline:
6
12
2023
pubmed:
6
12
2023
entrez:
6
12
2023
Statut:
aheadofprint
Résumé
The identification of cystic fibrosis screening-positive, inconclusive diagnosis (CFSPID) in infants is a controversial outcome of newborn screening for cystic fibrosis (CF). Today, despite improvements in the knowledge of CFSPID and the description of several cohorts, little data are available on cohorts with a follow-up period of more than 6 years. In this study, we report the outcomes of an Italian cohort of CFSPID individuals with CFSPID or formerly CFTR-related disorders (CFTR-RD) (CFSPID > CFTR-RD) or diagnosed with CF (CFSPID > CF). This was an observational and multicentre Italian study collecting clinical data on CFSPID born between the period January 1, 2011, and December 13, 2019. A total of 268 participants were included: 243 with persistent CFSPID, 7 with CFSPID > CFTR-RD, and 18 with CFSPID > CF. The trend of sweat chloride (SC) values, percentage of definitive diagnoses, lung function in school-aged children, and development of CF-related complications were evaluated. At the end of the observation period, almost 80% of the individuals with CFSPID did not have a conclusive diagnosis. A total of 29 children (10.8%) transitioned to a diagnosis of CF for pathological SC values (≥ 60 mmol/L) or multi-organ involvement, and 18 (6.7%) to CFTR-RD. Children who were followed up for > 6 years (median age, 7.5 years; range, 6.04-10.5) had normal lung function and were pancreatic sufficient, and the evolution in CF was only present in two cases. Most Italian preschool and school-aged children with CFSPID did not have a conclusive diagnosis, and progression to CF was unlikely in children > 6 years of age. An annual follow-up could be indicated to identify early evolution in clinical features consistent with a CFTR-RD. • Cystic Fibrosis newborn screening identifies also subjects with an inconclusive diagnosis (CFSPID). • Over time a variable percentage of CFSPIDs will be diagnosed as CF. • Little data is available on CFSPIDs with a follow-up period of more than six years. • 80% of Italian preschool and school-age CFSPIDs not have a conclusive diagnosis. • Italian preschool and school-age CFSPIDs have normal lung function and are pancreatic sufficient. • Annual follow-up after 6 years is recommended in CFSPID with abnormal LCI2.5 or with a CF-causing variant in trans with a VVCC.
Identifiants
pubmed: 38054992
doi: 10.1007/s00431-023-05359-5
pii: 10.1007/s00431-023-05359-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Southern KW, Munck A, Pollitt R, Travert G, Zanolla L, Dankert-Roelse J, Castellani C; ECFS CF Neonatal Screening Working Group (2007) A survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros 6:57–65. https://doi.org/10.1016/j.jcf.2006.05.008
doi: 10.1016/j.jcf.2006.05.008
Massie RJ, Curnow L, Glazner J, Armstrong DS, Francis I (2012) Lessons learned from 20 years of newborn screening for cystic fibrosis. Med J Aust 196:67–70. https://doi.org/10.5694/mja11.10686
doi: 10.5694/mja11.10686
pubmed: 22256939
Hale JE, Parad RB, Dorkin HL, Gerstle R, Lapey A, O’Sullivan BP, Spencer T, Yee W, Comeau AM (2010) Cystic fibrosis newborn screening: using experience to optimize the screening algorithm. J Inherit Metab Dis 33:S255–S261. https://doi.org/10.1007/s10545-010-9117-3
doi: 10.1007/s10545-010-9117-3
pubmed: 20521170
Fibrosis C, Foundation; Borowitz D, Parad RB, Sharp JK, Sabadosa KA, Robinson KA, Rock MJ, Farrell PM, Sontag MK, Rosenfeld M, Davis SD, et al (2009) Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. J Pediatr 155:S106–S116. https://doi.org/10.1016/j.jpeds.2009.09.003
doi: 10.1016/j.jpeds.2009.09.003
Munck A, Mayell SJ, Winters V, Shawcross A, Derichs N, Parad R, Barben J, Southern KW; ECFS Neonatal Screening Working Group (2015) Cystic fibrosis screen positive, inconclusive diagnosis (CFSPID): a new designation and management recommendations for infants with an inconclusive diagnosis following newborn screening. J Cyst Fibros 14:706–713. https://doi.org/10.1016/j.jcf.2015.01.001
doi: 10.1016/j.jcf.2015.01.001
Ren CL, Borowitz DS, Gonska T, Howenstine MS, Levy H, Massie J, Milla C, Munck A, Southern KW (2017) Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome and cystic fibrosis screen positive, inconclusive diagnosis. J Pediatr 181S:S45–S51. https://doi.org/10.1016/j.jpeds.2016.09.066
doi: 10.1016/j.jpeds.2016.09.066
pubmed: 28129812
Terlizzi V, Claut L, Tosco A, Colombo C, Raia V, Fabrizzi B, Lucarelli M, Angeloni A, Cimino G, Castaldo A et al (2021) A survey of the prevalence, management and outcome of infants with an inconclusive diagnosis following newborn bloodspot screening for cystic fibrosis (CRMS/CFSPID) in six Italian centres. J Cyst Fibros 20:828–834. https://doi.org/10.1016/j.jcf.2021.03.015
doi: 10.1016/j.jcf.2021.03.015
pubmed: 33883100
Munck A, Berger DO, Southern KW, Carducci C, de Winter-de Groot KM, Gartner S, Kashirskaya N, Linnane B, Proesmans M, Sands D, European CF Society Neonatal Screening Working Group (ECFS NSWG) et al (2022) European survey of newborn bloodspot screening for CF: opportunity to address challenges and improve performance. J Cyst Fibros 10:S1569–1993. https://doi.org/10.1016/j.jcf.2022.09.012
Bianchimani C, Dolce D, Centrone C, Campana S, Ravenni N, Orioli T, Camera E, Mergni G, Fevola C, Bonomi P, Taccetti G, Terlizzi V (2022) Impact of pancreatitis-associated protein on newborn screening outcomes and detection of CFTR-related metabolic syndrome (CRMS)/cystic fibrosis screen positive, inconclusive diagnosis (CFSPID): a monocentric prospective pilot experience. Int J Neonatal Screen 8:46. https://doi.org/10.3390/ijns8030046
Barben J, Castellani C, Munck A, Davies JC, de Winter-de Groot KM, Gartner S, Kashirskaya N, Linnane B, Mayell SJ, McColley S, European CF Society Neonatal Screening Working Group (ECFS NSWG) et al (2021) Updated guidance on the management of children with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID). J Cyst Fibros 20:810–819. https://doi.org/10.1016/j.jcf.2020.11.006
Gonska T, Keenan K, Au J, Dupuis A, Chilvers MA, Burgess C, Bjornson C, Fairservice L, Brusky J, Kherani T et al (2021) Outcomes of cystic fibrosis screening-positive infants with inconclusive diagnosis at school age. Pediatrics 1(148):e2021051740. https://doi.org/10.1542/peds.2021-051740
Ooi CY, Castellani C, Keenan K, Avolio J, Volpi S, Boland M, Kovesi T, Bjornson C, Chilvers MA, Morgan L et al (2015) Inconclusive diagnosis of cystic fibrosis after newborn screening. Pediatrics 135:e1377–e1385. https://doi.org/10.1542/peds.2014-2081
doi: 10.1542/peds.2014-2081
pubmed: 25963003
Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E, Sermet I, Schwarz M, Tzetis M, Wilschanski M et al (2011) Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros 10:S86-102. https://doi.org/10.1016/S1569-1993(11)60014-3
doi: 10.1016/S1569-1993(11)60014-3
pubmed: 21658649
Castellani C, De Boeck K, De Wachter E, Sermet-Gaudelus I, Simmonds NJ, Southern KW; ECFS Diagnostic Network Working Group (2022) ECFS standards of care on CFTR-related disorders: updated diagnostic criteria. J Cyst Fibros 21:908–921. https://doi.org/10.1016/j.jcf.2022.09.011
doi: 10.1016/j.jcf.2022.09.011
Johnson F, Southern KW, Ulph F (2019) Psychological impact on parents of an inconclusive diagnosis following newborn bloodspot screening for cystic fibrosis: a qualitative study. Int J Neonatal Screen 15:23. https://doi.org/10.3390/ijns5020023
doi: 10.3390/ijns5020023
Tosco A, Marino D, Polizzi S, Tradati V, Padoan R, Giust C, Fabrizzi B, Taccetti G, Merli L, Terlizzi V (2023) A multicentre Italian study on the psychological impact of an inconclusive cystic fibrosis diagnosis after positive neonatal screening. Children (Basel) 10:177. https://doi.org/10.3390/children10020177
doi: 10.3390/children10020177
pubmed: 36832306
Ginsburg DK, Salinas DB, Cosanella TM, Wee CP, Saeed MM, Keens TG, Gold JI (2022) High rates of anxiety detected in mothers of children with inconclusive cystic fibrosis screening results. J Cyst Fibros 15:S1569-1993. https://doi.org/10.1016/j.jcf.2022.12.002
doi: 10.1016/j.jcf.2022.12.002
Terlizzi V, Claut L, Colombo C, Tosco A, Castaldo A, Fabrizzi B, Lucarelli M, Cimino G, Carducci C, Dolce D et al (2021) Outcomes of early repeat sweat testing in infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/CF screen-positive, inconclusive diagnosis. Pediatr Pulmonol 56:3785–3791. https://doi.org/10.1002/ppul.25683
doi: 10.1002/ppul.25683
pubmed: 34549893
The Sweat Test Recommendations from Italian Cystic Fibrosis Society (SIFC) Sweat Test Working Group—Third Ed. (2022) Available online: https://www.sifc.it/wp-content/uploads/2022/06/Raccomandazioni-Italiane-sul-Test-del-Sudore-_Aprile-2022.pdf . Accessed on 31 May 2023
Scurati-Manzoni E, Fossali EF, Agostoni C, Riva E, Simonetti GD, Zanolari-Calderari M, Bianchetti MG, Lava SA (2014) Electrolyte abnormalities in cystic fibrosis: systematic review of the literature. Pediatr Nephrol 29:1015–1023. https://doi.org/10.1007/s00467-013-2712-4
doi: 10.1007/s00467-013-2712-4
pubmed: 24326787
Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, Howenstine M, McColley SA, Rock M, Rosenfeld M et al (2017) Diagnosis of cystic fibrosis: consensus guidelines from the cystic fibrosis foundation. J Pediatr. 181S:S4-S15.e1. https://doi.org/10.1016/j.jpeds.2016.09.064
Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E, Sermet I, Schwarz M, Tzetis M, Wilschanski M et al (2011) Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros Suppl 2:S86-102. https://doi.org/10.1016/S1569-1993(11)60014-3
doi: 10.1016/S1569-1993(11)60014-3
LeGrys VA, Yankaskas JR, Quittell LM, Marshall BC, Mogayzel PJ Jr, Foundation CF, Foundation CF (2007) Diagnostic sweat testing: the Cystic Fibrosis Foundation guidelines. J Pediatr 151:85–89. https://doi.org/10.1016/j.jpeds.2007.03.002
doi: 10.1016/j.jpeds.2007.03.002
pubmed: 17586196
Anagnostopoulou P, Latzin P, Jensen R, Stahl M, Harper A, Yammine S, Usemann J, Foong RE, Spycher B, Hall GL et al (2020) Normative data for multiple breath washout outcomes in school-aged Caucasian children. Eur Respir J 55:1901302. https://doi.org/10.1183/13993003.01302-2019
doi: 10.1183/13993003.01302-2019
pubmed: 31862765
Hardaker KM, Panda H, Hulme K, Wong A, Coward E, Cooper P, Fitzgerald DA, Pandit C, Towns S, Selvadurai H, Robinson PD (2019) Abnormal preschool lung clearance index (LCI) reflects clinical status and predicts lower spirometry later in childhood in cystic fibrosis. J Cyst Fibros 18:721–727. https://doi.org/10.1016/j.jcf.2019.02.007
Oude Engberink E, Ratjen F, Davis SD, Retsch-Bogart G, Amin R, Stanojevic S (2017) Inter-test reproducibility of the lung clearance index measured by multiple breath washout. Eur Respir J 50:1700433. https://doi.org/10.1183/13993003.00433-2017
doi: 10.1183/13993003.00433-2017
pubmed: 28982773
pmcid: 5898949
Frey U, Stocks J, Coates A, Sly P, Bates J (2000) Specifications for equipment used for infant pulmonary function testing. ERS/ATS Task Force on Standards for Infant Respiratory Function Testing. European Respiratory Society/ American Thoracic Society. Eur Respir J 16:731–740. https://doi.org/10.1034/j.1399-3003.2000.16d28.x
doi: 10.1034/j.1399-3003.2000.16d28.x
pubmed: 11106221
Terlizzi V, Parisi GF, Ferrari B, Castellani C, Manti S, Leonardi S, Taccetti G (2022) Effect of dornase alfa on the lung clearance index in children with cystic fibrosis: a lesson from a case series. Children (Basel) 9:1625. https://doi.org/10.3390/children9111625
doi: 10.3390/children9111625
pubmed: 36360353
Flume PA, Mogayzel PJ Jr, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC (2009) Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 180:802–808. https://doi.org/10.1164/rccm.200812-1845PP
doi: 10.1164/rccm.200812-1845PP
pubmed: 19729669
Beydon N, Davis SD, Lombardi E, Allen JL, Arets HG, Aurora P, Bisgaard H, Davis GM, Ducharme FM, Eigen H, American Thoracic Society/European Respiratory Society Working Group on Infant and Young Children Pulmonary Function Testing et al (2007) An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children. Am J Respir Crit Care Med 175:1304–45. https://doi.org/10.1164/rccm.200605-642ST
Munck A, Bourmaud A, Bellon G, Picq P, Farrell PM; DPAM Study Group (2020) Phenotype of children with inconclusive cystic fibrosis diagnosis after newborn screening. Pediatr Pulmonol 55:918–928. https://doi.org/10.1002/ppul.24634
doi: 10.1002/ppul.24634
Gunnett MA, Baker E, Mims C, Self ST, Gutierrez HH, Guimbellot JS (2023) Outcomes of children with cystic fibrosis screen positive, inconclusive diagnosis/CFTR related metabolic syndrome. Front Pediatr 11:1127659. https://doi.org/10.3389/fped.2023.1127659
doi: 10.3389/fped.2023.1127659
pubmed: 36969284
pmcid: 10034052
Ginsburg D, Wee CP, Reyes MC, Brewington JJ, Salinas DB (2022) When CFSPID becomes CF. J Cyst Fibros 21:e23–e27. https://doi.org/10.1016/j.jcf.2021.06.012
doi: 10.1016/j.jcf.2021.06.012
pubmed: 34756682
Tosco A, Castaldo A, Colombo C, Claut L, Carnovale V, Iacotucci P, Lucarelli M, Cimino G, Fabrizzi B, Caporelli N et al (2022) Clinical outcomes of a large cohort of individuals with the F508del/5T;TG12 CFTR genotype. J Cyst Fibros 21:850–855. https://doi.org/10.1016/j.jcf.2022.04.020
doi: 10.1016/j.jcf.2022.04.020
pubmed: 35523714
Terlizzi V, Padoan R, Claut L, Colombo C, Fabrizzi B, Lucarelli M, Bruno SM, Castaldo A, Bonomi P, Taccetti G, Tosco A (2020) CRMS/CFSPID subjects carrying D1152H CFTR variant: can the second variant be a predictor of disease development? Diagnostics (Basel) 10:1080. https://doi.org/10.3390/diagnostics10121080
doi: 10.3390/diagnostics10121080
pubmed: 33322690
Terlizzi V, Mergni G, Centrone C, Festini F, Taccetti G (2020) Trend of sweat chloride values in a cohort of patients carrying CFTR mutations of varying clinical consequence: is there a risk of increasing sweat chloride over time? Pediatr Pulmonol 55:1089–1093. https://doi.org/10.1002/ppul.24721
doi: 10.1002/ppul.24721
pubmed: 32150665
Hatton A, Bergougnoux A, Zybert K, Chevalier B, Mesbahi M, Altéri JP, Walicka-Serzysko K, Postek M, Taulan-Cadars M, Edelman A et al (2022) Reclassifying inconclusive diagnosis after newborn screening for cystic fibrosis. Moving forward J Cyst Fibros 21:448–455. https://doi.org/10.1016/j.jcf.2021.12.010
doi: 10.1016/j.jcf.2021.12.010
pubmed: 34949556
Salinas DB, Ginsburg DK, Wee CP, Saeed MM, Brewington JJ (2023) Gradual increase in sweat chloride concentration is associated with a higher risk of CRMS/CFSPID to CF reclassification. Pediatr Pulmonol 58:1074–1084. https://doi.org/10.1002/ppul.26296
doi: 10.1002/ppul.26296
pubmed: 36582049
Terlizzi V, Fevola C, Ferrari B, Castellani C, Santini G, Innocenti D, Masi E, Bonomi P, Lombardi E, Taccetti G (2023) Lung clearance index in children with cystic fibrosis previously diagnosed with CRMS/CFSPID: a monocentric prospective experience. Pediatr Pulmonol. https://doi.org/10.1002/ppul.26442 . Epub ahead of print. PMID: 37133232
Kasi AS, Wee CP, Keens TG, Salinas DB (2020) Abnormal lung clearance index in cystic fibrosis screen positive, inconclusive diagnosis (CFSPID) children with otherwise normal FEV1. Lung 198:163–167. https://doi.org/10.1007/s00408-019-00307-3
doi: 10.1007/s00408-019-00307-3
pubmed: 31844968
Aurora P, Stanojevic S, Wade A, Oliver C, Kozlowska W, Lum S, Bush A, Price J, Carr SB, Shankar A, Stocks J, Collaboration LCF (2011) Lung clearance index at 4 years predicts subsequent lung function in children with cystic fibrosis. Am J Respir Crit Care Med 183:752–758. https://doi.org/10.1164/rccm.200911-1646OC
doi: 10.1164/rccm.200911-1646OC
pubmed: 20935113
Bauer SE, Wesson M, Oles SK, Ren CL (2021) Outcomes of repeat sweat testing in cystic fibrosis newborn screen positive infants. Pediatr Pulmonol 56:1521–1526. https://doi.org/10.1002/ppul.25296
Vermeulen F, Lebecque P, De Boeck K, Leal T (2017) Biological variability of the sweat chloride in diagnostic sweat tests: a retrospective analysis. J Cyst Fibros 16:30–35. https://doi.org/10.1016/j.jcf.2016.11.008
doi: 10.1016/j.jcf.2016.11.008
pubmed: 28017620
Terlizzi V, Dolce D (2023) Variability of the sweat test in children with cystic fibrosis previously CRMS/CFSPID: a retrospective monocenter experience. J Cyst Fibros 26:S1569-1993. https://doi.org/10.1016/j.jcf.2023.04.018
doi: 10.1016/j.jcf.2023.04.018